Angela Pegram*

Associate Professor, Wingate University School of Pharmacy, USA

*Corresponding Author: Angela Pegram, Associate Professor, Wingate University School of Pharmacy, USA.

Received: October 25, 2022; Published: November 28, 2022

Abstract

This scoping review was conducted to summarize findings regarding the experiences of visible minority women with the Canadian primary healthcare system to identify the challenges they face in accessing care. Articles searched from databases and grey literature were selected if they (i) were peer-reviewed, (ii) were published between 1990 and 2019, (iii) discussed the experiences of visible minority women with primary healthcare, and (iv) studied Canadian populations. The information extracted was tagged and sorted into themes based on Bronfenbenner’s ecological systems theory which separates society into layers for analysis. Barriers to healthcare for visible minority women were found to arise from interpersonal, community, and systemic levels. The findings demonstrate that a lack of social support and insufficient culturally sensitive care, among other factors, prevent visible minority women from accessing health resources. We provide recommendations for where improvements might be made to deliver truly equitable healthcare to this population.

Keywords: Visible Minority; Barriers; Primary Healthcare; Canada

References

1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215341s000lbl.pdf
2. Peter Kolkhof and Lars Barfacker. “Mineralocorticoid receptors: 60 years of research and development”. Journal of Endocrinology 234 (2017): T125-140.
3. Juan Simon Rico-Mesa., et al. “Mineralocorticoid Receptor Antagonists: A Comprehensive Review of Finerenone”. Current Cardiology Reports 22 (2020): 140.
4. Kolkhof P., et al. “Nonsteroidal antagonists of the mineralocorticoid receptor”. Current opinion in Nephrology and Hypertension5 (2015): 417-424.
5. Kolkhof P., et al. “Finerenone, a novel selective non-steroidal mineralocorticoid receptor antagonist protects from rat cardio renal injury”. Journal of Cardiovascular Pharmacology (2014).
6. Gabriele Rohde., et al. “Determination of finerenone - a novel, selective, nonsteroidal mineralocorticoid receptor antagonist - in human plasma by high-performance liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study in venous and capillary human plasma”. Journal of Chromatography B 1172 (2021): 122643.
7. “HPLC calibration process parameters in terms of system suitability test”. Austin Chromatography 1.2 (2014).
8. USP - The United States Pharmacopeia and National Formulary USP 42 NF37, The United States Pharmacopoeial Convention, Inc.: Rockville, MD (2019).
9. ICH - International Council of Harmonization. “Stability testing of New Drug Substances and Products - Q1A (R2)” (2003).
10. ICH Harmonised Tripartite Guideline, Stability Testing: Photostability Testing of New Drug Substances and Products, Q1B, 1996 (2020).
11. ICH Harmonised Tripartite Guideline Validation of analytical procedures: text and methodology Q2 (R1), in: Validation of Compendia Procedures USP 40 - NF 35, (Chapter 1225) (2005): 1780-1783.

Citation

Citation: Angela Pegram. “A Case Report of Hypercalcemia from Hypervitaminosis A and D". Acta Scientific Pharmaceutical Sciences 6.12 (2022): 34-38.

Copyright

Copyright: © 2022 Angela Pegram. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.